低剂量吉西他滨单药治疗老年晚期非小细胞肺癌的观察  

Observation of low-dose gemcitabine in treating elderly patients with non-small cell lung cancer

作　　者：郝琳[1] 王怀瑾[1] 王冰[2] 许慧[2] 戚震伟[2] 

机构地区：[1]大连今华夏医院肿瘤内科,辽宁大连116021 [2]大连大学附属医院肿瘤中心,116044

出　　处：《临床肿瘤学杂志》2006年第1期27-28,31,共3页Chinese Clinical Oncology

摘　　要：目的:观察低剂量吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效。方法:国产吉西他滨600mg/m2,静脉滴注30分钟,第1、8、15天,28天为1周期,治疗65岁以上NSCLC患者31例。结果:31例患者共化疗95个周期,总有效率(CR+PR)29.0%(9/31),临床受益率61.3%(19/31)。毒副作用以白细胞和血小板下降为常见,但均可耐受。结论:低剂量国产吉西他滨单药治疗老年NSCLC有着较好疗效且病人耐受性较好。Objective：To investigate the clinical efficacy of elderly patients with advanced NSCLC treated with low-dose gemcitbine. Methods：31 patients aged over 65 with advanced NSCLC were treated with Zefei 600mg/m^2 on days 1, 8 and 15. The schedule was repeated every 28 days. Results ：The recent efficacy ： 31 patients were given 95 cycles, overall response rate was 29.0% （ 9/ 31 ） ; the clinical benefitial response was 61.3% （ 19/31 ）. The main toxicities were leucopenia and thrombocytopenia. Conclusion：The low-dose gemcitabine is a feasible, well-tolerated, and active scheme in the treatment of elderly patients with advanced NSCLC.

关 键 词：非小细胞肺癌 老年患者 吉西他滨 化学疗法 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]